Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis

Mingyang Feng 1,2†, Yue Chen 1,3†, Yang Yang 1,2 and Qiu Li 1,2*  

1 Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China, 2 West China Biomedical Big Data Center, Sichuan University, Chengdu, China, 3 National Medical Products Administration Key Laboratory for Clinical Research and Evaluation of Innovative Drugs, Clinical Trial Center, West China Hospital, Sichuan University, Chengdu, China  

Background: In the international, randomized, open-label, phase 3 study 309-KEYNOTE-775 trial, lenvatinib plus pembrolizumab (LP) showed improved progression-free survival (PFS) and overall survival (OS) compared with chemotherapy in pretreated patients with advanced endometrial cancer. This study aimed to investigate whether LP is cost-effective compared with chemotherapy.  

Materials and Methods: The clinical data for this model was derived from the 309-KEYNOTE-775 trial. Costs and utilities were either derived from the standard fee database or extracted from previously published literature. A three-state Markov model was developed to simulate the disease process of patients with advanced endometrial cancer. One-way sensitivity analyses were conducted to investigate the impact of variables in the analysis model. Probabilistic sensitivity analysis was performed based on 10,000 Monte-Carlo simulations. A subgroup analysis was performed to test whether LP is cost-effective in patients with mismatch repair–proficient (pMMR) disease.  

Results: Lenvatinib plus pembrolizumab provided an incremental 0.64 quality-adjusted life years (QALYs) with an incremental cost of $241,278.18, compared with chemotherapy, resulting in the incremental cost-effectiveness ratio (ICER) of $378,251.44/QALY, which exceeded the willingness to pay (WTP) threshold. While in the pMMR subgroup, the ICER increased to $413,256.68/QALY. The variance of the utility of PFS state, the cost of LP, and the utility of the progressive disease state were the most influential factors in the sensitivity analysis.  

Conclusion: Under the current WTP threshold, LP is not cost-effective compared with chemotherapy in pretreated patients with advanced endometrial cancer.  

Keywords: cost-effectiveness, lenvatinib, pembrolizumab, endometrial cancer, immunotherapy combined therapy
INTRODUCTION

The incidence and mortality of endometrial cancer are both increasing in the United States, with an estimated 65,950 new cases and 12,550 deaths in 2022 (1). Women with advanced endometrial cancer are faced with low 5-year relative survival rates of 20% and limited treatment options following initial systemic therapy (2). Pembrolizumab, a monoclonal antibody targeting programmed cell death 1 (PD-1), was approved for the second-line treatment of metastatic or recurrent endometrial cancer with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) status (3, 4). In the phase II trial KEYNOTE-158, pembrolizumab showed a 57% response rate in MSI-H endometrial cancers (5). However, for the more prevalent microsatellite stable (MSS) or mismatch repair-proficient (pMMR) cancers, pembrolizumab has shown less effective (6).

Lenvatinib, an oral multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR) 1-3, fibroblast growth factor receptors (FGFR) 1-4, platelet-derived growth factor receptor (PDGFR)-α, RET, and KIT (7), displayed anti-tumor activity and has been approved for several solid tumors as a single agent or in combination. While in a phase II study of lenvatinib for recurrent endometrial cancer, the overall response rate was only 14.3% (8). The combination of lenvatinib with immune checkpoint inhibitors has been evaluated in preclinical models and has shown more potent antitumor activity than either agent alone (9, 10).

The phase 3 study 309-KEYNOTE-775 (NCT03517449) showed lenvatinib plus pembrolizumab (LP) prolonged progression-free survival (PFS) and overall survival (OS), compared with chemotherapy among platinum-based chemotherapy pretreated patients with advanced endometrial cancer (11). One of the greatest challenges oncologists face today is that new therapeutic approaches are frequently associated with higher costs than previous standard techniques and, in some cases, with only marginal improvement in outcomes. This cost-effectiveness analysis aimed to compare LP vs. chemotherapy in pretreated patients with advanced endometrial cancer.

MATERIALS AND METHODS

This analysis used a mathematical modeling approach using inputs from the 309-KEYNOTE-775 trial, databases, and academic literature, following the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist (12).

Patients and Interventions

The clinical data of patients with advanced endometrial cancer were derived from the multicenter, open-label, randomized phase 3 study (309-KEYNOTE-775) (11). Eligible patients had
TABLE 1 | Clinical efficacy and proportion of patients with grade 3–4 adverse events.

| Clinical efficacy-months | LP | Chemotherapy |
|--------------------------|----|--------------|
| Overall population       |    |              |
| Median OS                | 18.3 | 11.4 |
| Median PFS               | 7.2  | 3.8 |
| pMMR population          |    |              |
| Median OS                | 17.4 | 12 |
| Median PFS               | 6.6  | 3.8 |
| Proportion of patients with grade 3–4 AE |    |              |
| Hypertension              | 0.379 | 0.023 |
| Diarrhea                  | 0.076 | 0.021 |
| Decreased appetite        | 0.079 | 0.005 |
| Weight decrease           | 0.103 | 0.003 |
| Anemia                    | 0.062 | 0.147 |
| Neutropenia               | 0.017 | 0.258 |
| Neutrophil count decreased| 0.017 | 0.212 |
| WBC decreased             | 0.001 | 0.103 |

LP: lenvatinib plus pembrolizumab; OS, overall survival; PFS, progression-free survival; pMMR, mismatch repair-proficient; AE, adverse event; WBC, white blood cell.

advanced, recurrent, or metastatic endometrial cancer who had disease progression after the receipt of one previous platinum-based chemotherapy regimen, and were randomized (1:1) to the LP group or chemotherapy group. In the LP group, patients received cycles of lenvatinib at a dose of 20 mg, administered orally once daily, plus pembrolizumab at a dose of 200 mg, administered intravenously every 3 weeks. In the chemotherapy group, patients received doxorubicin at a dose of 60 mg/m² of body-surface area, administered intravenously every 3 weeks, and paclitaxel at a dose of 80 mg/m², administered intravenously weekly (with a cycle of 3 weeks on and 1 week off). Before randomization, the treating physician would choose chemotherapy with doxorubicin or paclitaxel for each eligible patient, and MMR status was determined with biopsy specimens for each patient by pathologist evaluation. As a result, 827 patients (697 in the pMMR population and 130 in the dMMR population) were randomly assigned to a treatment group and the demographic and disease characteristics of the patients at baseline were balanced between the treatment groups (11). Treatment with one previous platinum-based therapy was reported for 79.3% of the patients in the LP group and 75.7% of those in the chemotherapy group (11).

Model Construction
A Markov decision model was developed with TreeAge Pro 2020 software (TreeAge, Williamstown, MA, USA) to simulate the disease process of patients with advanced endometrial cancer. The model structure comprised three mutually exclusive health states: PFS, progressive disease (PD), and death. All of the patients started in the PFS state and the cycle length was assumed as 1 month. Patients either stayed in the initial health status or progressed during each cycle over a lifetime horizon, as shown in Figure 1. To extrapolate the transition probabilities, the original data were extracted from the survival curves in the 309-KEYNOTE-775 trial by WebPlotDigitizer (Version:4.4; https://automeris.io/WebPlotDigitizer) (11), and these data were then used to fit parametric survival models using the algorithm derived by Hoyle et al. (13). Furthermore, we validated the results of transition probabilities using the formula: $P = 1 - (0.5)^{1/(\text{median time to event})}$, which was derived from the equation: $R = -\ln[0.5]/(\text{time to event/number of treatment cycles})$.

Costs
Costs were estimated from the U.S.-payer’s perspective. Costs in this study were derived from the Red Book® online database (http://www.micromedexsolutions.com, accessed on Feb 10, 2022) or previously published literature. Direct medical costs were considered, such as costs of testing for dMMR/MSI-H status, drug acquisition costs, costs of administration, disease management costs, and costs of managing adverse events (AEs) (grade ≥ 3). To more accurately calculate the costs for drug acquisition in patients with lenvatinib, we used the median dose intensity of lenvatinib of 13.8 mg/day, as specified in the 309-KEYNOTE-775 trial (11), rather than a standard dose of 20 mg/day. For patients with the progressed disease, there was no standard third-line therapy recommended by NCCN guidelines (4), and the detailed information on subsequent therapy was not specified in the 309-KEYNOTE-775 trial. Therefore, we assumed that they crossed to the other group as subsequent therapy after the failure of treatment, and the acceptance rates of subsequent therapy were assumed to be 28.0 and 48.1% in the LP group and chemotherapy group, respectively (11). Moreover, the costs of palliative care were taken into consideration as transition costs in patients who entered the death state (14). Based on the mean body surface area of 1.71 m² (15), the costs for each cycle were calculated. Costs and benefits were discounted to present values at 3% each year. Half-cycle corrections were also applied. All costs were inflated to December 2021 using consumer price index (CPI) calculators (available online at: http://www.bls.gov/data/# calculators), which are listed in Table 2. The incremental cost-effectiveness ratio (ICER) was defined as a ratio of incremental costs to incremental benefits.

Health Outcomes
In all populations of the 309-KEYNOTE-775 trial, the median PFS was 7.2 months in the LP group, and 3.2 months in the chemotherapy group. The median OS of the LP group and the chemotherapy group was 18.3 and 11.4 months, respectively (11). Other clinical efficacy and the proportion of patients with grade 3–4 AEs are shown in Table 1.
endometrial cancer were identified as 0.817 for PFS, 0.779 for PD, and 0 for death (14).

**Sensitivity Analysis**

Input data and ranges in the sensitivity analyses are shown in Table 2. One-way sensitivity analyses were conducted to investigate the impact of variables on the Markov model by varying variables with a range of ±25%, as shown in the tornado diagram. Probabilistic sensitivity analysis was conducted using a Monte-Carlo simulation of 10,000 patients by the simultaneous and random preset variation of parameters to evaluate optimal strategies at different hypothetical willingness-to-pay thresholds (WTP). Cost-effectiveness acceptability curves were developed to reflect the probability that treatment becomes cost-effective by varying ceiling ratios (19). A WTP threshold of $100,000 per QALY was applied.

**Subgroup Analysis**

A subgroup cost-effectiveness analysis was performed for the pMMR population, and the transition probabilities were

### Table 2: Input parameters and ranges.

| Costs ($, 2021 Dec) | LP | Chemo | Lower value | Upper value | Distribution | References |
|---------------------|----|-------|-------------|-------------|--------------|------------|
| **Costs for PFS per month** |     |       |             |             |              |            |
| Lenvatinib          | $16,166.98 | $12,125.24 | $20,208.73 | Gamma Red book |
| Pembrolizumab       | $16,429.87 | $12,322.40 | $20,537.34 | Gamma Red book |
| Doxorubicin         | $164.16 | $123.12 | $205.20 | Gamma Red book |
| Paclitaxel          | $205.20 | $153.90 | $256.50 | Gamma Red book |
| Costs of administration per 10 mins | $55.98 | $41.99 | $69.98 | Gamma Thurgar et al. (14) |
| Hypertension        | $7,965.60 | $5,974.20 | $9,957.00 | Gamma Arondekar et al. (16) |
| Diarrhea            | $7,795.80 | $5,846.85 | $9,744.75 | Gamma Arondekar et al. (16) |
| Anemia              | $14,314.20 | $10,735.65 | $17,892.75 | Gamma Le et al. (17) |
| Neutropenia         | $14,429.73 | $10,822.30 | $18,037.16 | Gamma Thurgar et al. (14) |
| Neutrophil count decreased | $14,429.73 | $10,822.30 | $18,037.16 | Gamma Thurgar et al. (14) |
| WBC decreased       | $7,071.65 | $5,303.74 | $8,839.56 | Gamma Thurgar et al. (14) |
| Costs of AE management | $3,611.44 | $9,614.54 | Gamma Thurgar et al. (14) |
| Costs of drug acquisition | $32,820.76 | $765.31 | Gamma Thurgar et al. (14) |
| Costs of disease management | $360.42 | $270.32 | $450.53 | Gamma Thurgar et al. (14) |
| **Total**           | $36,792.62 | $10,740.27 | Gamma Thurgar et al. (14) |
| **Costs for PD per month** |     |       |             |             |              |            |
| Costs of disease management | $360.42 | $270.32 | $450.53 | Gamma Thurgar et al. (14) |
| Subsequent therapy  | $2,906.36 | $17,523.89 | Gamma This study |
| **Total**           | $3,266.78 | $17,884.31 | Gamma This study |
| Testing for dMMR/MSI-H status-one set | $666.40 | $499.80 | $833.00 | Gamma Thurgar et al. (14) |
| Costs of palliative care-one set | $11,266.07 | $8,449.55 | $14,082.59 | Gamma Thurgar et al. (14) |
| **Transition probabilities in all population** |     |       |             |             |              |            |
| PPFS-PFS            | 0.911 | 0.814 | Fixed | This study |
| PPFS-PD             | 0.052 | 0.127 | Fixed | This study |
| PPFS-death          | 0.037 | 0.059 | Fixed | This study |
| PPD-PD              | 0.951 | 0.908 | Fixed | This study |
| PPD-death           | 0.049 | 0.092 | Fixed | This study |
| **Transition probabilities in pMMR population** |     |       |             |             |              |            |
| PPFS-PFS            | 0.895 | 0.809 | Fixed | This study |
| PPFS-PD             | 0.066 | 0.135 | Fixed | This study |
| PPFS-death          | 0.039 | 0.056 | Fixed | This study |
| PPD-PD              | 0.937 | 0.904 | Fixed | This study |
| PPD-death           | 0.063 | 0.096 | Fixed | This study |
| **Utilities**       |     |       |             |             |              |            |
| PFS state           | 0.817 | 0.613 | 1.000 | Beta | Thurgar et al. (14) |
| PD state            | 0.779 | 0.584 | 0.974 | Beta | Thurgar et al. (14) |
| Death               | 0.000 |       |             | Fixed |              |            |

LP, lenvatinib plus pembrolizumab; PFS, progression-free survival; WBC, white blood cell; AE, adverse event; PD, progressive disease; MSI-H, microsatellite instability–high; dMMR, mismatch repair–deficient; P, transition probability; pMMR, mismatch repair-proficient.
extrapolated using the survival data supplied by the 309-KEYNOTE-775 trial. In the pMMR subgroup ($n = 697, 84.3\%$), the median PFS was 6.6 months in the LP group, 3.8 months in the chemotherapy group, and the median OS was 17.4 and 12.0 months in the LP group and the chemotherapy group, respectively (11).

**RESULTS**

**Costs Outcomes**

In terms of PFS state costs, the costs of drug acquisition accounted for most in the LP group ($32,820.76 per month), while the costs of grade 3–4 AEs management accounted for the majority of the chemotherapy group ($9,614.54 per month), as shown in Table 2. The disease management costs were assumed to be the same in the two groups at $360.42 per month. As for the costs for PD state, the total cost was $3,266.78 per month for the LP group and $135,517.86 per month for the chemotherapy group, including costs of disease management and subsequent therapy. Overall, the cumulative costs were $432,785.93 for the LP group, which was higher than that of $191,507.75 for the chemotherapy group (as shown in Table 3).

**Health Outcomes**

Based on the aforementioned algorithm, calibrated transition probabilities are listed in Table 2, and the curves of the fitted parametric model are displayed in Supplementary Materials (Supplementary Figures S1, S2). The overall effectiveness in the LP group was higher than that in the chemotherapy group (1.43 vs. 0.79 QALYs), as shown in Table 3.

**Base-Case Results**

The base-case results of the analysis are presented in Table 3. Treatment with LP was estimated to generate an incremental 0.64 QALYs with incremental costs of $241,278.18 compared with the chemotherapy group, resulting in an ICER of $378,251.44/QALY.

**Sensitivity Analysis**

The one-way sensitivity analyses are displayed in the tornado diagram in Figure 2, where the variables were changed across a range of ±25%. The utility of PFS state, the cost of lenvatinib and pembrolizumab, and the utility of PD state were the most influential factors in this study. The result of the Monte-Carlo simulation of 10,000 patients showed that the mean cost and effectiveness gained were $430,736.70 ± 96,209.99 and 1.43 ± 0.25 QALYs for the LP group, while $192,160.92 ± 34,481.06 and 0.79 ± 0.14 QALY for the chemotherapy group. The probabilistic sensitivity analysis indicated that LP was not likely to be accepted until the WTP rose above $360,000 (Figure 3A).

**Subgroup Analysis**

In the subgroup analysis of the pMMR population, the cumulative costs and effectiveness were $367,346.00 and 1.21 QALYs for the LP group, and $189,197.40 and 0.78 QALYs for the chemotherapy group, resulting in the ICER at $413,256.68/QALY, as shown in Table 4. The probabilistic sensitivity analysis indicated that LP was more likely to be accepted when the WTP rose over $400,000 (Figure 3B).

**DISCUSSION**

Based on the phase 3 trial 309-KEYNOTE-775, our study indicated LP cost more ($432,785.93 vs. $191,507.75) and yielded more health outcomes than chemotherapy (1.43 vs. 0.79 QALYs), resulting in the ICER of $378,251.44/QALY, which was much beyond the prespecified WTP threshold ($100,000/QALY), suggesting that LP is not a cost-effective choice compared with chemotherapy. One-way sensitivity analysis and probabilistic sensitivity analysis both suggested that this result was robust. For patients with pMMR disease, the combination strategy had shown less cost-effective than chemotherapy, as the ICER increased to $413,256.68/QALY.

The most influential factors driving our models were the utility of the PFS state, the cost of lenvatinib and pembrolizumab, and the utility of the PD state. The ICER still exceeded the WTP threshold no matter how much the value of these variances changed. As the costs of lenvatinib and pembrolizumab both exerted a significant effect on the sensitivity analysis, decreasing the price of lenvatinib and pembrolizumab could be an efficient strategy to reduce ICER.

Pembrolizumab monotherapy may be less effective in patients with recurrent MSS/pMMR tumors (6), and the strategy of lenvatinib in combination with pembrolizumab was confirmed effective in patients with advanced endometrial cancer (20). In this cost-effectiveness analysis, we found that the ICER of combination therapy continued to increase in the pMMR subgroup, compared with the chemotherapy group. We suspected that it was due to the significantly reduced effectiveness.
of the LP group in the patients with pMMR disease, compared with that in the overall population (1.21 vs. 1.43 QALYs), as the median PFS and median OS both reduced in the LP group in patients with pMMR disease (Table 1).

To our knowledge, there has been a series of cost-effective analyses evaluating different kinds of treatment in advanced endometrial cancer. The cost-effectiveness of pembrolizumab monotherapy was evaluated in pretreated advanced endometrial cancer, and positive results were obtained that pembrolizumab monotherapy was a highly cost-effective treatment option when compared with chemotherapy, especially in patients with dMMR/MSI-high disease (14, 21). However, when pembrolizumab is combined with lenvatinib, the conclusions would be changed. For instance, LP has been evaluated compared
TABLE 4 | Results of the cost-effectiveness analysis in patients with pMMR.

|                         | LP         | Chemo      |
|-------------------------|------------|------------|
| **Base-case analysis**  |            |            |
| **Costs ($)**           |            |            |
| Costs for PFS state     | 329,567.32 | 54,243.43  |
| Costs for PD state      | 37,778.68  | 134,964.02 |
| Total costs             | 367,346.00 | 189,197.40 |
| Incremental costs       | 178,148.60 |            |
| **Effectiveness (QALYs)**|          |            |
| Effectiveness for PFS state | 0.60    | 0.32       |
| Effectiveness for PD state | 0.61    | 0.46       |
| Total effectiveness     | 1.21       | 0.78       |
| Incremental effectiveness| 0.43    |            |
| **Cost/Effectiveness**  | 303,358.70 | 242,609.04 |
| **ICER ($ per QALY)**   | 413,256.68 |            |
| **Monte-Carlo simulation (10000x)** |        |            |
| Mean costs ($)          | 366,289.42 | 189,091.23 |
| SD                      | 80,918.20  | 34,048.63  |
| Mean effectiveness (QALYs) | 1.21 | 0.78       |
| SD                      | 0.21       | 0.14       |

LP, lenvatinib plus pembrolizumab; PFS, progression-free survival; PD, progressive disease; QALY, quality-adjusted life-year; ICER, incremental cost-effectiveness ratio; SD, standard deviation.

with carboplatin/paclitaxel in the first-line therapy for patients with advanced endometrial cancer (22). In this study, the authors found that LP was dominated by carboplatin/paclitaxel in patients with MSS disease, and was not cost-effective in the MSI-high model. Moreover, the cost-effectiveness of LP in patients with recurrent pretreated MSS endometrial cancer was evaluated by Barrington et al. (23), and consistent with our conclusion, they found that LP was not cost-effective. Notably, their analysis was conducted based on the results of phased 2 trial (20), and our results would make a powerful addition to this topic. All of these studies warn us that performing reasonable economic evaluation has become an important and indispensable part of the cancer-treat resources allocation process, and could guide clinical practice.

The limitations of our study are as follows. First, the 309-KEYNOTE-775 trial collected the quality of life-related information with the health-related quality of life instrument QLQ-C30. The utility of disease pattern in our study was calculated from EQ-5D data in a clinical trial, which may not accurately reflect the patients’ quality of life in the 309-KEYNOTE-775 trial. Second, as there was no standard third-line therapy after the failure of the second-line treatment of recurrent or metastatic endometrial carcinoma according to NCCCN guidelines (4), we assumed the patients of the two groups switched to the other. The assumption may not be very accurate, but we believe it could somewhat reflect the real situation. The acceptance rates of subsequent therapy were extracted from the 309-KEYNOTE-775 trial (11). Another is that, in our analysis, we only considered the costs of AEs management, and ignored the disutility caused by AEs, as there remained controversial opinions on the values of disutility in different AEs and diseases. While in our sensitivity analysis, we found that the utility of the PFS state impacts most of the model outcomes, but the ICER still exceeded the WTP threshold while the value of utility changed (0.613–1.000), which could confirm the robustness of our results. Moreover, costs and WTP threshold could vary between different medical centers or different countries, and this may affect the generalizability. Our sensitivity analysis was conducted by varying variables with a range of ±25%, demonstrating that the results remained robust while variables changed, and a future perspective cost-effectiveness study is expected to further verify our results.

In conclusion, our study evaluated the cost-effectiveness of LP versus chemotherapy in pretreated patients with advanced endometrial cancer and found that LP is not a cost-effective choice from a U.S.-payers’ perspective, which could be considered in the decision-making process to make recommendations regarding the therapy for patients with advanced endometrial cancer. Reducing the price of LP or offering appropriate drug assistance policies might be considerable options to optimize the cost-effectiveness of LP.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

Material preparation, data collection, and analysis were performed by MF and YC. The first draft of the manuscript was written by MF. The revised manuscript was written by MF, YC, and YY. All authors contributed to the study conception and design, and read and approved the final manuscript.

FUNDING

This work was supported by the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (Grant Nos. ZYJC18008 and ZYJC18010). The funding source was not involved in the study design, data collection, data analysis, data interpretation, the writing of this article, or the decision to submit the article for publication.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2022.881034/full#supplementary-material
REFERENCES

1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. (2022) 72:7–33. doi: 10.3322/caac.21708
2. American Cancer Society. Endometrial Cancer Survival Rates, by Stage. Available online at: https://www.cancer.org/cancer/endometrial-cancer/detection-diagnosis-staging/survival-rates.html (accessed February 15, 2022).
3. Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S, et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer. (2021) 31:12–39. doi: 10.1136/ijgc-2020-002230
4. National Comprehensive Cancer Network (NCCN): Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Version 1. 2022. Available online at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1473 (accessed February 15, 2022).
5. Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord JP, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. (2020) 38:1–10. doi: 10.1200/JCO.20.0105
6. Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, et al. Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study. J Clin Oncol. (2017) 35:2535–41. doi: 10.1200/JCO.2017.72.5952
7. Hao Z, Wang P. Lenvatinib in Management of Solid Tumors. Oncologist. (2020) 25:e302–e10. doi: 10.1634/theoncologist.2019-0407
8. Vergote I, Powell MA, Teneriello MG, Miller DS, Garcia AA, Mikheeva ON, et al. Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecol Oncol. (2020) 156:575–82. doi: 10.1016/j.gyno.2019.12.039
9. Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, et al. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS ONE. (2019) 14:e0212513. doi: 10.1371/journal.pone.0212513
10. Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, Ichikawa K, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. (2018) 109:3993–4002. doi: 10.1111/cas.13806
11. Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. (2022) 386:437–48. doi: 10.1056/NEJMoa2108330
12. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Value Health. (2013) 16:e1–5. doi: 10.1016/j.jval.2013.02.010
13. Hoyle MW, Henley W. Improved curve fits to summary survival data: application of economic evaluation of health technologies. BMC Med Res Methodol. (2011) 11:139. doi: 10.1186/1471-2288-11-139
14. Thurgar E, Gouldson M, Matthijssse S, Amonkar M, Marinello P, Upadhyay N, et al. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer. J Med Econ. (2021) 24:675–88. doi: 10.1080/13696998.2021.1917140
15. Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS ONE. (2010) 5:e8933. doi: 10.1371/journal.pone.0008933
16. Arondekar B, Curkendall S, Monberg M, Mirakhor B, Ogleby AK, Lenhart GM, et al. Economic burden associated with adverse events in patients with metastatic melanoma. J Manag Care Spec Pharm. (2015) 21:158–64. doi: 10.18553/jmcp.2015.21.2.138
17. Le QA, Bae YH, Kang JH. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer. Breast Cancer Res Treat. (2016) 159:65–73. doi: 10.1007/s10549-016-3958-9
18. Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. (2010) 96:5–21. doi: 10.1093/bmbldq/105
19. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. (2001) 33:337–43. doi: 10.3109/07853890109002087
20. Makker V, Taylor MH, Aghajanian C, Osknin A, Mier J, Cohn AL, et al. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. J Clin Oncol. (2020) 38:2981–92. doi: 10.1200/JCO.2019.19.02627
21. Barrington DA, Dilley SE, Smith HJ, Straughn JM Jr. Pembrolizumab in advanced recurrent endometrial cancer: a cost-effectiveness analysis. Gynecol Oncol. (2019) 153:381–4. doi: 10.1016/j.ygyno.2019.02.013
22. Ackroyd SA, Huang ES, Kurnit KC, Lee NK. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: a Markov analysis. Gynecol Oncol. (2021) 162:249–55. doi: 10.1016/j.ygyno.2021.05.038
23. Barrington DA, Haight PJ, Calhoun C, Tubbs C, Bixel KL. Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: a cost-effectiveness analysis. Gynecol Oncol. (2021) 162:626–30. doi: 10.1016/j.ygyno.2021.06.014

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Feng, Chen, Yang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.